文献速递肝病

平均动脉压与特利加压素在肝肾综合征-急性肾损伤逆转中的关系:一项事后分析

The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis.
PubMed 文献 · Hepatology · 2025-03-07

该事后分析利用REVERSE和CONFIRM两项3期试验的487例患者数据,评估特利加压素对平均动脉压(MAP)的影响及其与肝肾综合征-急性肾损伤(HRS-AKI)逆转的关系。特利加压素组随机化后MAP显著高于安慰剂组,MAP每升高5 mm Hg与HRS-AKI逆转风险增加相关,且MAP显著介导HRS-AKI逆转。

要点

  • 特利加压素较安慰剂在第1天即升高MAP约6.0 mm Hg,并持续至第3天。
  • MAP每升高5 mm Hg,HRS-AKI逆转的风险比为1.17(95% CI:1.11-1.22)。
  • MAP显著介导HRS-AKI逆转,平均中介比例为33%(95% CI:14-76)。

核心结论

  • 特利加压素导致早期、持续的MAP升高,MAP是HRS-AKI逆转的关键药效学靶点。

研究设计与样本

  • 对REVERSE和CONFIRM两项3期临床试验的患者水平数据进行事后分析,共纳入487例患者(特利加压素组60%,安慰剂组40%)。

主要发现

  • 基线时特利加压素组与安慰剂组的中位MAP无差异(77 mm Hg vs. 76 mm Hg,p=0.3)。
  • 随机化后特利加压素组MAP显著高于安慰剂组(第1天:85 mm Hg vs. 75 mm Hg;第3天:81 mm Hg vs. 76 mm Hg;均p<0.001)。
  • 混合效应模型显示,特利加压素较安慰剂在第1天使MAP升高6.0 mm Hg,治疗组与时间无显著交互作用(p>0.05)。
  • 时依Cox模型显示,MAP每升高5 mm Hg,HRS-AKI逆转的风险比为1.17(95% CI:1.11-1.22)。
  • 中介分析显示,无论治疗组别,MAP均显著介导HRS-AKI逆转,平均中介比例为33%(95% CI:14-76)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Terlipressin reverses hepatorenal syndrome-acute kidney injury (HRS-AKI) by increasing mean arterial pressure (MAP). To further characterize the relationship between terlipressin and MAP and their impact on HRS-AKI reversal, we used patient-level data from phase 3 clinical trials REVERSE and CONFIRM. APPROACH AND RESULTS: In this post hoc analysis we employed a linear mixed-effects model to assess terlipressin's impact on MAP, exploring the relationship between MAP, treatment group, and time, incorporating a random intercept for individual patients. Time-dependent Cox models analyzed MAP's role in HRS-AKI reversal. We conducted a mediation analysis to evaluate how time-weighted MAP mediated HRS-AKI reversal. This analysis included 487 patients (60% terlipressin, 40% placebo). At baseline, there were no differences in median MAP between terlipressin and placebo (77 mm Hg vs. 76 mm Hg, p =0.3); the terlipressin group had significantly higher MAPs after randomization (day 1: 85 mm Hg vs. 75 mm Hg; day 3: 81 mm Hg vs. 76 mm Hg; all: p <0.001). In mixed-effects models, terlipressin was associated with a 6.0 mm Hg increase in MAP over placebo occurring on day 1, with no significant interaction between the treatment group and time ( p >0.05). In time-dependent Cox models, each 5 mm Hg increase in MAP was associated with 1.17× the hazard of HRS-AKI reversal (95% CI: 1.11-1.22). In mediation analysis, MAP significantly mediated HRS-AKI reversal, regardless of treatment group (average proportion mediated: 33%, 95% CI: 14-76). CONCLUSIONS: These data highlight that terlipressin leads to an early, sustained increase in MAP, which is a key pharmacodynamic target for HRS-AKI reversal.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Cullaro G, Allegretti AS, Patidar KR, et al. The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis. Hepatology. 2025. PMID: 40053863. doi:10.1097/HEP.0000000000001295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。